Hanmi Pharm. Co., Ltd.

A128940

KR7128940004

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
315,000 ^KRW	+0.16%		+5.00%	-10.64%

Mar. 19	Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 31	Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd.	CI

Hanmi Pharm Co Ltd Q2 Operating Profit Up 86% Y/Y To 29.6 Billion Won

July 18, 2022 at 12:50 am EDT

July 18 (Reuters) - Hanmi Pharm Co Ltd:

* HANMI PHARM CO LTD: Q2 OPERATING PROFIT UP 86% Y/Y TO 29.6 BILLION WON ($22.49 million) Further company coverage: ($1 = 1,316.4000 won)

Latest news about Hanmi Pharm. Co., Ltd.

Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd.	Jan. 30	CI
Aptose Biosciences Inc. announced that it expects to receive $4 million in funding from Hanmi Pharm. Co., Ltd.	Jan. 24	CI
Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Hanmi Pharm's Q3 Income Surges 94%	Nov. 02	MT
Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Aptose Biosciences Inc. announced that it expects to receive $6.999998 million in funding from Hanmi Pharm. Co., Ltd.	23-08-09	CI
Hanmi Pharm's Net Income Declines in Q2	23-08-01	MT
Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).	23-07-30	CI
Hanmi Pharm. Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Hanmi Pharm's Net Income Climbs in Q1	23-04-26	MT
Assertio Holdings, Inc. (NasdaqCM : ASRT) entered into a definitive agreement to acquire Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI) for approximately $250 million.	23-04-24	CI
Hanmi Pharm. Co., Ltd.'s Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirms Non-inferiority Efficacy and Safety Compared to Monotherapy in The Lancet' & 'European Heart Journal	23-03-17	CI
Hanmi Pharm's Net Income Plunges 23.7% in Q4	23-02-09	MT
Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Hanmi Pharm's Net Profit Jumps 11.5% in Q3	22-11-02	MT
Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
Hanmi Pharm's Net Income Surges 179.1% in June Quarter	22-07-19	MT
Hanmi Pharm Co Ltd Q2 Operating Profit Up 86% Y/Y To 29.6 Billion Won	22-07-18	RE
KT Corporation and Hanmi Pharmaceutical Promote Business Cooperation with Digital Pharm	22-06-21	CI
Digital Pharm announced that it has received funding from KT Corporation, Hanmi Pharm. Co., Ltd.	22-06-18	CI
US FDA Recommends Clinical Trials for Hanmi Pharm's Invetigational Fatty Liver Disease Drug	22-05-06	MT
Hanmi Pharm's Net Income Rises 6.9% in Q1	22-04-28	MT
Eight South Korean Firms to Donate $2.4 Million Worth of Medicine to Ukraine	22-04-12	MT
Marinomed Biotech AG Signs New Agreement for Carragelose in South Korea	22-04-12	CI

Hanmi Pharm Co Ltd is a Korea-based company principally engaged in the manufacturing and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceuticals segment manufactures and sells tablets, capsules, injections, syrups, powders and raw materials used in the treatment of hypertension, reflux esophagitis, influenza type A and influenza type B virus infections and hyperlipidemia, among others. The Other segment is engaged in the materials processing. The Export segment produces and sells products such as powders and injections, and exports technologies.

Sector

Pharmaceuticals

Calendar

2024-04-30 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Hanmi Pharm. Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

315,000 KRW

Average target price

408,486 KRW

Spread / Average Target

+29.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
HANMI PHARM. CO., LTD.	-10.64%	2.91B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+17.97%	42.77B
OTSUKA HOLDINGS CO., LTD.	+20.21%	22.23B
SANDOZ GROUP AG	+13.12%	14.44B
CIPLA LIMITED	+12.19%	13.05B
ZYDUS LIFESCIENCES LIMITED	+35.45%	11.59B
ONO PHARMACEUTICAL CO., LTD.	-8.80%	6.95B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+6.29%	4.97B

Generic Pharmaceuticals